MedDataX Logo

Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction

NCT ID: NCT02292043

Last Updated: 2014-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-05-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction. The specific index is 6 miniutes walk distance, echocardiography, NYHA, NTproBNP level, peripherial WBC, RBC, PLT, Cre, UA, K+, Na+ upon entrance to hospital and 4 weeks after HTEA treatment, and 3 months after discharge. The morbidity and re-hospitalization would also calculated 3 months after discharge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congestive Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

idiopathic dilated cardiomyopathy group

idiopathic dilated cardiomyopathy group treated with HTEA

HTEA

Intervention Type DRUG

HTEA

post-myocardial infarction group

post-myocardial infarction group treated with TEA

HTEA

Intervention Type DRUG

HTEA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HTEA

HTEA

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 90 chronic cardiac failure patients in our hospital were selected and divided into two groups.

Exclusion Criteria

* Vavular diseases
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Harbin Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wei Liu

Prof. Liu

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

wei liu

Role: PRINCIPAL_INVESTIGATOR

First Affiliated Hospital of Harbin Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ren Xiaohui

Harbin, Heilongjiang, China

Site Status RECRUITING

the first affiliated hospital of Harbin Medical University

Harbin, Heilongjiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

wei liu, Ph.D.

Role: CONTACT

86-18904502999

xiaohui ren

Role: CONTACT

86-451-85552320

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xiaohui Ren

Role: primary

[email protected]
86-85552320

Xiaohui Ren

Role: primary

86-451-85552320

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

wei liu

Identifier Type: -

Identifier Source: org_study_id